News

Bekkenbodemmatjes zijn per direct verboden in Amerika. De Amerikaanse toezichthouder FDA heeft de productie en de verkoop van chirurgische matjes van de fabrikanten Boston Scientific en Coloplast gestopt. Deze matjes worden, ook in Nederland, geplaatst bij vrouwen met een verzakking in de bekkenbodem. Klik hier om het volledige artikel te lezen. ‘Nederlands verbod op onveilige […]

We are pleased to announce that the 12-month follow-up data of our clinical study ‘Treatment with a polycaprolactone (PCL)-based bioresorbable urethral bulking agent for mild to moderate stress urinary incontinence (SUI)’ has been accepted for ePoster Presentation (Abstract 122) on Wednesday 4th of September 14:50h (ePoster Station 6) at the upcoming ICS Annual Meeting, 3-6 September 2019 in Gothenburg, Sweden.

We are pleased to announce that the 12-month follow-up data of our clinical study ‘Treatment with a polycaprolactone (PCL)-based bioresorbable urethral bulking agent for mild to moderate stress urinary incontinence (SUI)’ has been accepted for Oral Presentation (O14) on Thursday 25th of April 14:15-15:30h at the upcoming UKCS Meeting, 24-26 April 2019 in Manchester, United Kingdom.

Stress urinary incontinence (SUI) is treatable, it is not a taboo. It is imperative to seek advice and help for any condition which negatively affects your quality of life, such as SUI.

A major milestone, AQLANE Medical has received EN ISO 13485:2016 certification for its Quality Management System (QMS).